Gilead gets filgotinib rights from Galapagos; deal amended following CRL for RA indication
A few months after losing a major partner for the project, Galapagos NV has penned a new deal for its Phase II rheumatoid arthritis and Crohn's disease compound filgotinib, granting Gilead Sciences Inc. global rights to develop, manufacture, and sell the therapy.
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com